Voice Technology Company ArkX Laboratories Inks European Sales Agreement With Redtree Solutions
ArkX Laboratories, a leading provider of advanced far-field voice-capture technology, has appointed Redtree Solutions, the largest Pan-European electronic representative in the semiconductor industry, as the exclusive sales representative for its production-ready EveryWord™ voice solution in the Europe, Middle East and Africa (EMEA) marketplace.
This announcement coincides with growing demand from Fortune 1000 companies, OEMs, and start-ups in the region who want to bring their voice-enabled smart products and devices to market. The EveryWord™ portfolio offers a production-ready path that delivers an unmatched voice experience while mitigating risk, reducing development costs, and accelerating their time-to-market.
Featuring Cirrus Logic's SoundClear™ and FlexArray™ technologies, ArkX's advanced line of production-ready voice capture solutions outperform other existing solutions in far-field voice capture and deliver a far-superior voice experience to consumers. The products are Alexa-compatible and meet or exceed all requirements for the Amazon Voice Services (AVS) qualifications. In addition to Alexa, EveryWord™ is compatible with other platforms such as Google, Siri, Cortana, AliGenie, Baidu/Kitt.ai, Tencent, and Sensory. EveryWord™ voice solutions can be customized for a company's eco-system and applied to a wide range of products, including speakers, soundbars, televisions, appliances, voice controllers, and gadgets. For smart home applications, the modules can be installed in hubs, ceilings, and in-wall.
"The ArkX EveryWord portfolio solves the toughest problems facing innovative OEMs today, including capturing voice at a greater distance, around corners, in the presence of blaring TV, and other noisy and reverberative environments without having to lower playback volume," said ArkX CEO Eric Bauswell. "EveryWord truly outperforms the performance of standard far-field voice solutions by so large a margin that consumers will never want to go back to the 'old' technology."
Covering 19 countries with more than 500 active customers, Redtree will help accelerate ArkX Labs' market penetration in the region by generating greater awareness of the company's solutions and providing on-the-ground support to ArkX Labs' expanding customer base.
"We were impressed with the innovation and superior far-field performance of the EveryWord™ solutions. It's a huge leap forward and certainly the best far-field solutions ever seen on the marketplace over our 10+ years' experience in this segment," said Steve Judge, Redtree Solutions Managing Director. "The addition of ArkX's EveryWord™ voice solutions represent a strategic addition to our electronic component portfolio that will have appeal to many of our customers operating in the smart home, broadband telecom, consumer, robotic, automotive, and industrial marketplaces."
ArkX Executive Vice President Michael Lang added, "Redtree's experience, expertise, and support structure provides the perfect fit to help us expand our reach beyond existing North American and Asian markets."
The product line offers clear performance advantages for capturing voice commands from three times the standard distance, around corners, noisy and reflective environments, and without lowering playback volume. Additionally, EveryWord™ technology provides a unique ability to identify and to suppress speech from TV or other single-point noise sources.
EveryWord™ technology does not require source-ducking for reliable interaction, provides linear, circular, square, triangular, or 3D mic array geometries, and requires fewer microphones. The technology features ultra-low power battery operation for wake-on-word, and the flexibility for placement of microphones allows for in-wall, ceiling, or dashboard solutions. The 3D mic array versus other linear beam-forming approaches enables fewer blind spots and increased performance while incorporating fewer redundant microphone arrays for coverage.
About ArkX Laboratories
ArkX Laboratories, a joint venture between product development pioneer, Surfaceink, and consumer electronics manufacturer Ark Electronics USA brings an exceptional voice experience to the marketplace. Our next generation of advanced, high-performance far-field voice capture solutions, featuring Cirrus Logic and NXP technology, are Amazon pre-qualified and production-ready. ArkX provides Fortune 1000, OEMs, and start-ups who want their own branded, voice-enabled IoT products and smart devices with the ability to reduce their development time and costs and accelerate their time-to-market while mitigating the risk. For more information, please visit www.arkxlabs.com.
About Redtree Solutions
Redtree Solutions is the largest Pan-European Representative company in the region. More than 40 people provide service, speak local languages, and cover 19 countries with more than 500 active customers. Redtree invests in next-generation technologies for the benefit of its customers and is dedicated to their success. The Redtree application team is devoted to helping customers find the most optimized architecture for your Electronic systems, with the help of their partners' solutions and expertise. Redtree is headquartered near Oxford, UK. For more information, please visit www.redtree-solutions.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201116006041/en/
Contact information
Jean-Marie Houillon, +33 (0)1 30 47 25 33
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom